AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15992694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and levamisole (n=374).
Number of subjects: 1501
Study 15992694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid (n=368).
Number of subjects: 1501
Study 15992694 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional chemotherapy (intraperitoneal or intraportally).
Number of subjects: 1501
Study 15992694 — intervention group
Group type: COMPARATOR
Intervention: Non-regional treatment (systemic chemotherapy alone).
Number of subjects: 1501
Study 15992694 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both regional and systemic chemotherapy).
Number of subjects: 1501
Study 10472217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin and gentamicin-vancomycin antibiotic prophylaxis (Group D)
Number of subjects: 100
Study 10472217 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole and no aprotinin (Group A)
Number of subjects: 100
Study 10472217 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole and high-dose aprotinin (Group B)
Number of subjects: 100
Study 10472217 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and vancomycin, but no aprotinin (Group C)
Number of subjects: 100
Study 10163609 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-Dose Inhaler (MDI)
Number of subjects: 68
Study 10163609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-Held Nebulizer (HHN)
Number of subjects: 68
Study 1833901 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg captopril (C)
Number of subjects: 10
Study 1833901 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg captopril (C)
Number of subjects: 10
Study 1833901 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg enoximone (E)
Number of subjects: 10
Study 1833901 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg enoximone (E)
Number of subjects: 10
Study 6315025 — intervention group
Group type: EXPERIMENTAL
Intervention: suloctidil 200 mg three times per day
Number of subjects: 10
Study 6315025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30137262 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Guided Acupuncture Imagery Treatment (VGAIT)
Number of subjects: 27
Study 30137262 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Number of subjects: 27
Study 30137262 — intervention group
Group type: COMPARATOR
Intervention: VGAIT Control Condition (watching a video of a cotton swab touching the skin)
Number of subjects: 27
Study 30137262 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 27
Study 29845877 — intervention group
Group type: EXPERIMENTAL
Intervention: AIHA patients (CD8+CD57+ cells frequency)
Number of subjects: 18
Study 29845877 — intervention group
Group type: EXPERIMENTAL
Intervention: AIHA patients with partial or no response to therapy (CD8+CD57+ cells frequency)
Number of subjects: 18
Study 29845877 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders (CR) (CD8+CD57+ cells frequency)
Number of subjects: 18
Study 29845877 — intervention group
Group type: COMPARATOR
Intervention: Control group (CD8+CD57+ cells frequency)
Number of subjects: 18
Study 27310905 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive treatment (systolic BP < 120 mmHg)
Number of subjects: 9361
Study 27310905 — intervention group
Group type: COMPARATOR
Intervention: Less intensive treatment (systolic BP < 140 mmHg)
Number of subjects: 9361
Study 24632748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with oseltamivir and azithromycin (AZM)
Number of subjects: 107
Study 24632748 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 107
Study 23302158 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Epley maneuver
Number of subjects: 168
Study 23302158 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Semont maneuver
Number of subjects: 168
Study 23302158 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff maneuver
Number of subjects: 168
Study 23302158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical therapy)
Number of subjects: 168
Study 20714768 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening contractions
Number of subjects: 48
Study 20714768 — intervention group
Group type: COMPARATOR
Intervention: Lengthening contractions
Number of subjects: 48
Study 20714768 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface EMG of tibialis anterior during shortening contractions
Number of subjects: 48
Study 20714768 — intervention group
Group type: COMPARATOR
Intervention: Surface EMG of triceps surae
Number of subjects: 48
Study 18612874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted spaced retrieval
Number of subjects: 12
Study 18612874 — intervention group
Group type: COMPARATOR
Intervention: Uniform expanded retrieval
Number of subjects: 12
Study 16009794 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent vena cava filter
Number of subjects: 400
Study 16009794 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 400
Study 12519138 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. buprenorphine 2.5 micro g.kg‐1 (group B)
Number of subjects: 30
Study 12519138 — intervention group
Group type: EXPERIMENTAL
Intervention: caudal buprenorphine 2.5 micro g.kg‐1 (group C)
Number of subjects: 30
Study 12519138 — intervention group
Group type: COMPARATOR
Intervention: caudal 0.5% bupivacaine alone (group A)
Number of subjects: 30
Study 10354967 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 (8 micrograms/kg s.c.)
Number of subjects: 12
Study 10354967 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 with prednisone (15 mg p.o.)
Number of subjects: 12
Study 10354967 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisone
Number of subjects: 12
Study 10354967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10354967 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 12
Study 7489164 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide semipermeable mesh interface over skin grafts
Number of subjects: 45
Study 7489164 — intervention group
Group type: COMPARATOR
Intervention: No interface (control group)
Number of subjects: 45
Study 2012568 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% O2 condition
Number of subjects: 6
Study 2012568 — intervention group
Group type: COMPARATOR
Intervention: Air (control condition)
Number of subjects: 6
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg
Number of subjects: 1835
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg
Number of subjects: 1835
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg (phase 1 study)
Number of subjects: 1835
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg (phase 1 study)
Number of subjects: 1835
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg and 0.5 mg/100 mg
Number of subjects: 1835
Study 30694918 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (oral estradiol and progesterone capsules)
Number of subjects: 1835
Study 28485429 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg PI2
Number of subjects: 44
Study 28485429 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg PI2
Number of subjects: 44
Study 28485429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25559067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchtime walks (three weekly 30-min group-led walks for 10 weeks)
Number of subjects: 56
Study 25559067 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control period)
Number of subjects: 56
Study 23205617 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training
Number of subjects: 337
Study 23205617 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face group training
Number of subjects: 337
Study 22082198 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 3236
Study 22082198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3236
Study 19825330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) 2,250 to 3,000 mg/day
Number of subjects: 182
Study 19825330 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (SH) 4,800 to 6,400 mg/day
Number of subjects: 182
Study 17110264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study group (recent graduates)
Number of subjects: 89
Study 17110264 — intervention group
Group type: COMPARATOR
Intervention: Control group (practicing orthodontists)
Number of subjects: 89
Study 15041928 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate end points
Number of subjects: 0
Study 15041928 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite end points
Number of subjects: 0
Study 15041928 — intervention group
Group type: EXPERIMENTAL
Intervention: Major (hard) end points
Number of subjects: 0
Study 11497536 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 408
Study 11497536 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized studies
Number of subjects: 408
Study 11497536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study types
Number of subjects: 408
Study 11497536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective studies
Number of subjects: 408
Study 9228502 — intervention group
Group type: EXPERIMENTAL
Intervention: hRLX‐2 (10(‐7) M)
Number of subjects: 22
Study 9228502 — intervention group
Group type: EXPERIMENTAL
Intervention: hRLX‐2 (10(‐8) M and 10(‐9) M)
Number of subjects: 22
Study 8422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean dose, 5.2 mg, n = 27)
Number of subjects: 48
Study 8422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (mean dose, 175 mg, n = 11)
Number of subjects: 48
Study 8422223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean dose, 8.0 pills, n = 10)
Number of subjects: 48
Study 8422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (follow-up mean daily dose, 6.1 mg vs 1.6 mg, n = 14)
Number of subjects: 48
Study 8422223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (8-month completers and study dropouts)
Number of subjects: 48
Study 8422223 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month study completers vs study dropouts
Number of subjects: 48
Study 2441098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA)
Number of subjects: 10
Study 31799694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius G60 + inulin (1 billion CFUs + 1g)
Number of subjects: 45
Study 31799694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius G60 (1 billion CFUs)
Number of subjects: 45
Study 31799694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31183389 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg sucralose dissolved in 60 mL water
Number of subjects: 45
Study 31183389 — intervention group
Group type: COMPARATOR
Intervention: 60 mL water as placebo
Number of subjects: 45
Study 28522917 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiangbin prescription (XBP)
Number of subjects: 40
Study 26583672 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 μg) subcutaneously
Number of subjects: 18
Study 26583672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 1 mL)
Number of subjects: 18
Study 23269596 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg orally every 12 hours for 24 weeks
Number of subjects: 73
Study 23269596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance scores aggregated over Sessions 3-9
Number of subjects: 45
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance scores from Session 3
Number of subjects: 45
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Single assessment of the alliance
Number of subjects: 45
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregating 4 or more assessments of the alliance
Number of subjects: 45
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Session-to-session change in the alliance
Number of subjects: 45
Study 21639607 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment alliance scores
Number of subjects: 45
Study 19324125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bupivacaine administration (30 mL every 6 hours)
Number of subjects: 30
Study 19324125 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine infusion (5 mL/h)
Number of subjects: 30
Study 19324125 — intervention group
Group type: COMPARATOR
Intervention: Control (no local anesthetic infusion)
Number of subjects: 30
Study 17017271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular repositioning tape (FRT)
Number of subjects: 125
Study 12634667 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg three times daily
Number of subjects: 162
Study 12634667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 10695845 — intervention group
Group type: EXPERIMENTAL
Intervention: Farabloc fabric
Number of subjects: 20
Study 10695845 — intervention group
Group type: COMPARATOR
Intervention: Placebo fabric
Number of subjects: 20
Study 9347672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 0
Study 9347672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8408493 — intervention group
Group type: EXPERIMENTAL
Intervention: Small aspiration needle
Number of subjects: 30
Study 8408493 — intervention group
Group type: COMPARATOR
Intervention: Large aspiration needle
Number of subjects: 30
Study 3020832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam administration (10 mg)
Number of subjects: 8
Study 3020832 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo not explicitly mentioned)
Number of subjects: 8
Study 31072748 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 723
Study 31072748 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 723
Study 28674320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic and resistance training) for 24 weeks, 50-80 min, 5 times a week
Number of subjects: 50
Study 25228685 — intervention group
Group type: EXPERIMENTAL
Intervention: online behavioral training (oBT)
Number of subjects: 195
Study 25228685 — intervention group
Group type: COMPARATOR
Intervention: waitlist control (WLC)
Number of subjects: 195
Study 23457586 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 6 Hz
Number of subjects: 0
Study 23457586 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 10 Hz
Number of subjects: 0
Study 23457586 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 0
Study 23457586 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 25 Hz
Number of subjects: 0
Study 22136261 — intervention group
Group type: EXPERIMENTAL
Intervention: DHRMA (reduced GI) supply of chapatti, stone ground, high protein wheat flour and white basmati rice (high bran, unpolished)
Number of subjects: 50
Study 22136261 — intervention group
Group type: COMPARATOR
Intervention: Commercially available (leading brand) versions of chapatti wheat flour and basmati rice
Number of subjects: 50
Study 19356829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and energy-enriched formula (PE-formula)
Number of subjects: 18
Study 19356829 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (S-formula)
Number of subjects: 18
Study 16707411 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel matrix transdermal formulation of fentanyl (50 mug/h)
Number of subjects: 24
Study 16707411 — intervention group
Group type: COMPARATOR
Intervention: Conventional reservoir formulation of fentanyl
Number of subjects: 24
Study 14504680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg, administered twice daily for 7 days)
Number of subjects: 20
Study 14504680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11826514 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention to help formulate questions about drug therapy
Number of subjects: 45
Study 11826514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 9923224 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for school personnel
Number of subjects: 117
Study 9923224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 117
Study 8277179 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg orally twice a day)
Number of subjects: 29
Study 2760919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ho group
Number of subjects: 0
Study 2760919 — intervention group
Group type: COMPARATOR
Intervention: Low-Ho group
Number of subjects: 0
Study 4274488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar rotational manipulation followed by four daily detuned short-wave diathermy sessions (15 minutes each)
Number of subjects: 0
Study 4274488 — intervention group
Group type: COMPARATOR
Intervention: Detuned short-wave diathermy only (five 15-minute daily sessions)
Number of subjects: 0
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Medicaid insurance
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Income <$50,000
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: No car
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Unplanned pregnancy
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Unemployment
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Multiple children
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Missed prenatal visits
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of prenatal care
Number of subjects: 197
Study 29750924 — intervention group
Group type: COMPARATOR
Intervention: Higher scores for social support and goal-directed motivation
Number of subjects: 197
Study 27708677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 0
Study 25589719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF; folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Number of subjects: 106
Study 25589719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 23603862 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccination with gp100209-2M and MAGE-3243-258 peptides
Number of subjects: 70
Study 23603862 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide as adjuvant
Number of subjects: 70
Study 20948588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with monomeric allergoid (three different shortened up-dosing schedules)
Number of subjects: 86
Study 20948588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sublingual immunotherapy, only rescue medications)
Number of subjects: 86
Study 18371477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d for 1 year after a 300 mg loading dose before PCI
Number of subjects: 2002
Study 18371477 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d for 28 days and placebo for the remainder of a year after a placebo loading dose at the time of PCI
Number of subjects: 2002
Study 18371477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 2002
Study 17023710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate plus ascorbyl palmitate (AP) at molar ratios of 2:1
Number of subjects: 14
Study 17023710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate plus ascorbyl palmitate (AP) at molar ratios of 4:1
Number of subjects: 14
Study 17023710 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate alone
Number of subjects: 14
Study 14593039 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening (assessment and visual acuity testing)
Number of subjects: 4340
Study 14593039 — intervention group
Group type: COMPARATOR
Intervention: Targeted screening (only participants with health-related problems offered assessment)
Number of subjects: 4340
Study 10895994 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT)
Number of subjects: 10
Study 10895994 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 10
Study 8941027 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg
Number of subjects: 9
Study 8941027 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 1.0 mg
Number of subjects: 9
Study 8941027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1327980 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta adrenergic antagonist)
Number of subjects: 0
Study 1327980 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta-1 antagonist)
Number of subjects: 0
Study 1327980 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (beta adrenoreceptor agonist)
Number of subjects: 0
Study 3894481 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol/theophylline
Number of subjects: 17
Study 3894481 — intervention group
Group type: COMPARATOR
Intervention: Theophylline/placebo
Number of subjects: 17
Study 31342499 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion education group activities (90 minutes, twice a week for 8 sessions)
Number of subjects: 40